New therapeutics for osteoporosis

Current Opinion in Pharmacology

Volumn 16, Issue 1, 2014, Pages 58-63

  Ng, Kong Wah ^a   Martin, T John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN ANTIBODY; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LY 603281 31 8; ODANACATIB; PLACEBO; PROTEIN ANTIBODY; ROMOSOZUMAB; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN; ANABOLIC AGENT; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; CATHEPSIN K; DKK1 PROTEIN, HUMAN; GENETIC MARKER; PARATHYROID HORMONE; SIGNAL PEPTIDE; SOST PROTEIN, HUMAN;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FRACTURE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETIC MARKER; METABOLISM;

ANABOLIC AGENTS; ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; CATHEPSIN K; GENETIC MARKERS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOPOROSIS; PARATHYROID HORMONE; WNT PROTEINS;

EID: 84897513590     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.03.004     Document Type: Review

References (61)

1. H.M. Frost Dynamics of bone remodeling Bone Biodynamics Little 1964 Brown Boston 315 333
2. A.M. Parfitt The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis Metab Bone Dis Relat Res 4 1982 1 6
3. E.F. Eriksen Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease Endocr Rev 7 1986 379 408
4. E.M. Hauge, D. Qvesel, E.F. Eriksen, L. Mosekilde, and F. Melsen Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers J Bone Miner Res 16 2001 1575 1582 (Pubitemid 32786425)
5. T. Martin, J.H. Gooi, and N.A. Sims Molecular mechanisms in coupling of bone formation to resorption Crit Rev Eukaryot Gene Expr 19 2009 73 88
6. J. Reiser, B. Adair, and T. Reinheckel Specialized roles for cysteine cathepsins in health and disease J Clin Invest 120 2010 3421 3431
7. T. Yamaza, T. Goto, T. Kamiya, Y. Kobayashi, H. Sakai, and T. Tanaka Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur Bone 23 1998 499 509 (Pubitemid 28529454)
8. J. Vääräniemi, J.M. Halleen, K. Kaarlonen, H. Ylipahkala, S.L. Alatalo, G. Andersson, H. Kaija, P. Vihko, and H.K. Väänänen Intracellular machinery for matrix degradation in bone-resorbing osteoclasts J Bone Miner Res 19 2004 1432 1440 (Pubitemid 41094344)
9. L. Xia, J. Kilb, H. Wex, Z. Li, A. Lipyansky, V. Breuil, L. Stein, J.T. Palmer, D.W. Dempster, and D. Brömme Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones Biol Chem 380 1999 679 687 (Pubitemid 29322358)
10. P. Garnero, O. Borel, I. Byrjalsen, M. Ferreras, F.H. Drake, M.S. McQueney, N.T. Foged, P.D. Delmas, and J.M. Delaissé The collagenolytic activity of cathepsin K is unique among mammalian proteinases J Biol Chem 273 1998 32347 32352 (Pubitemid 29177183)
11. P. Maroteaux, and M. Lamy 2 cases of a condensing osseous disease: pycnodysostosis Arch Fr Pediatr 19 1962 267 274
12. B.D. Gelb, G.P. Shi, H.A. Chapman, and R.J. Desnick Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273 1996 1236 1238
13. P. Saftig, E. Hunziker, O. Wehmeyer, S. Jones, A. Boyde, W. Rommerskirch, J.D. Moritz, P. Schu, and K. von Figura Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice Proc Natl Acad Sci USA 95 1998 13453 13458 (Pubitemid 28522993)
14. M. Gowen, F. Lazner, R. Dodds, R. Kapadia, J. Feild, M. Tavaria, I. Bertoncello, F. Drake, S. Zavarselk, and I. Tellis et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization J Bone Miner Res 14 1999 1654 1663 (Pubitemid 29455813)
15. W. Chen, S. Yang, Y. Abe, M. Li, Y. Wang, J. Shao, E. Li, and Y.P. Li Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence Hum Mol Genet 16 2007 410 423 (Pubitemid 46323177)
16. B. Pennypacker, M. Shea, Q. Liu, P. Masarachia, P. Saftig, S. Rodan, G. Rodan, and D. Kimmel Bone density, strength, and formation in adult cathepsin K (-/-) mice Bone 44 2009 199 207
17. T. Duong Le Therapeutic inhibition of cathepsin K - reducing bone resorption while maintaining bone formation Bonekey Rep 1 2012 67
18. K.W. Ng Potential role of odanacatib in the treatment of osteoporosis Clin Interv Aging 7 2012 235 247
19. C.A. Zerbini, and M.R. McClung Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence Ther Adv Musculoskelet Dis 5 2013 199 209
20. R. Baron, S. Ferrari, and R.G. Russell Denosumab and bisphosphonates: different mechanisms of action and effects Bone 48 2011 677 692
21. P. Leung, M. Pickarski, Y. Zhuo, P.J. Masarachia, and L.T. Duong The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking Bone 49 2011 623 635
22. J.Y. Gauthier, N. Chauret, and W. Cromlish The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg Med Chem Lett 18 2008 923 928 (Pubitemid 351179363)
23. I. Podgorski Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1 2009 21 34
24. T. Cusick, C.M. Chen, B.L. Pennypacker, M. Pickarski, D.B. Kimmel, and B.B. Scott Duong le T: odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey J Bone Miner Res 27 2012 524 537
25. P.J. Masarachia, B.L. Pennypacker, M. Pickarski, K.R. Scott, G.A. Wesolowski, S.Y. Smith, R. Samadfam, J.E. Goetzmann, B.B. Scott, and D.B. Kimmel et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys J Bone Miner Res 27 2012 509 523
26. S.B. Rodan, and L.T. Duong Cathepsin K - a new molecular target for osteoporosis IBMS BoneKEy 5 2008 16 24
27. S.A. Stoch, S. Zajic, J. Stone, D.L. Miller, K. Van Dyck, M.J. Gutierrez, M. De Decker, L. Liu, Q. Liu, and B.B. Scott et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin Pharmacol Ther 86 2009 175 182
28. H.G. Bone, M.R. McClung, C. Roux, R.R. Recker, J.A. Eisman, N. Verbruggen, C.M. Hustad, C. DaSilva, A.C. Santora, and B.A. Ince Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J Bone Miner Res 25 2010 937 947
29. K. Brixen, R. Chapurlat, A.M. Cheung, T.M. Keaveny, T. Fuerst, K. Engelke, R. Recker, B. Dardzinski, N. Verbruggen, and S. Ather et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial J Clin Endocrinol Metab 98 2013 571 580
30. J.A. Eisman, H.G. Bone, D.J. Hosking, M.R. McClung, I.R. Reid, R. Rizzoli, H. Resch, N. Verbruggen, C.M. Hustad, and C. DaSilva et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect J Bone Miner Res 26 2011 242 251
31. S.J. Neele, R. Evertz, G. De Valk-De Roo, J.C. Roos, and J.C. Netelenbos Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women Bone 30 2002 599 603 (Pubitemid 34270498)
32. S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, R.F. Gagel, V. Gilsanz, T. Guise, and S. Koka et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491 (Pubitemid 351229318)
33. P.D. Miller, M.A. Bolognese, E.M. Lewiecki, M.R. McClung, B. Ding, M. Austin, Y. Liu, J. San Martin Amg Bone Loss Study Group Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 2008 222 229
34. H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.C. Yang, L. Grazette, J. San Martin, and J.C. Gallagher Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass J Clin Endocrinol Metab 96 2011 972 980
35. A. Grey, M.J. Bolland, D. Wattie, A. Horne, G. Gamble, and I.R. Reid The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women J Clin Endocrinol Metab 94 2009 538 544
36. A.G. Costa, N.E. Cusano, B.C. Silva, S. Cremers, and J.P. Bilezikian Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis Nat Rev Rheumatol 7 2011 447 456
37. C.A. Frolik, E.C. Black, R.L. Cain, J.H. Satterwhite, P.L. Brown-Augsburger, M. Sato, and J.M. Hock Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure Bone 33 2003 372 379 (Pubitemid 37103254)
38. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, and H.K. Genant et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441 (Pubitemid 32402100)
39. B.M. Misof, P. Roschger, F. Cosman, E.S. Kurland, W. Tesch, P. Messmer, D.W. Dempster, J. Nieves, E. Shane, and P. Fratzl et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 2003 1150 1156 (Pubitemid 36337769)
40. Y.L. Ma, Q. Zeng, D.W. Donley, L.G. Ste-Marie, J.C. Gallagher, G.P. Dalsky, R. Marcus, and E.F. Eriksen Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis J Bone Miner Res 21 2006 855 864 (Pubitemid 43787992)
41. R.L. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH Bone 40 2007 1434 1446 (Pubitemid 46756429)
42. H. Keller, and M. Kneissel SOST is a target gene for PTH in bone Bone 37 2005 148 158 (Pubitemid 40962421)
43. Y. Gong, R.B. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A.M. Reginato, H. Wang, T. Cundy, F.H. Glorieux, and D. Lev et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development Cell 107 2001 513 523 (Pubitemid 33152786)
44. L.M. Boyden, J. Mao, J. Belsky, L. Mitzner, A. Farhi, M.A. Mitnick, D. Wu, K. Insogna, and R.P. Lifton High bone density due to a mutation in LDL-receptor-related protein 5 N Engl J Med 346 2002 1513 1521 (Pubitemid 34755690)
45. M. Kato, M.S. Patel, R. Levasseur, I. Lobov, B.H. Chang, D.A. Glass 2nd, C. Hartmann, L. Li, T.H. Hwang, and C.F. Brayton et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor J Cell Biol 157 2002 303 314 (Pubitemid 34839826)
46. P. Babij, W. Zhao, C. Small, Y. Kharode, P.J. Yaworsky, M.L. Bouxsein, P.S. Reddy, P.V. Bodine, J.A. Robinson, and B. Bhat et al. High bone mass in mice expressing a mutant LRP5 gene J Bone Miner Res 18 2003 960 974 (Pubitemid 37294932)
47. F. Morvan, K. Boulukos, P. Clément-Lacroix, S. Roman Roman, I. Suc-Royer, B. Vayssière, P. Ammann, P. Martin, S. Pinho, P. Pognonec, and P. Mollat et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass J Bone Miner Res 21 2006 934 945 (Pubitemid 43788000)
48. E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma, B. Barlogie, and J.D. Shaughnessy Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 349 2003 2483 2494 (Pubitemid 38010074)
49. S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J.D. Shaughnessy Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 109 2007 2106 2111 (Pubitemid 46348212)
50. P. Clément-Lacroix, M. Ai, F. Morvan, S. Roman-Roman, B. Vayssière, C. Belleville, K. Estrera, M.L. Warman, R. Baron, and G. Rawadi Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice Proc Natl Acad Sci USA 102 2005 17406 17411 (Pubitemid 41740879)
51. N.H. Kulkarni, J.E. Onyia, Q. Zeng, X. Tian, M. Liu, D.L. Halladay, C.A. Frolik, T. Engler, T. Wei, and A. Kriauciunas et al. Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo J Bone Miner Res 21 2006 910 920 (Pubitemid 43787998)
52. X. Li, Y. Zhang, H. Kang, W. Liu, P. Liu, J. Zhang, S.E. Harris, and D. Wu Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling J Biol Chem 280 2005 19883 19887 (Pubitemid 41379516)
53. S.M. Ott Sclerostin and Wnt signaling - the pathway to bone strength J Clin Endocrinol Metab 90 2005 6741 6743 (Pubitemid 41759344)
54. X. Li, K.S. Warmington, Q.T. Niu, F.J. Asuncion, M. Barrero, M. Grisanti, D. Dwyer, B. Stouch, T.M. Thway, and M. Stolina et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats J Bone Miner Res 25 2010 2647 2656
55. D. Padhi, G. Jang, B. Stouch, L. Fang, and E. Posvar Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody J Bone Miner Res 26 2011 19 26
56. G. Silvestrini, P. Ballanti, M. Leopizzi, M. Sebastiani, S. Berni, M. Di Vito, and E. Bonucci Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone J Mol Histol 38 2007 261 269 (Pubitemid 47106897)
57. R.L. van Bezooijen, P. ten Dijke, S.E. Papapoulos, and C.W. Löwik SOST/sclerostin, an osteocyte-derived negative regulator of bone formation Cytokine Growth Factor Rev 16 2005 319 327 (Pubitemid 40910321)
58. M.K. Sutherland, J.C. Geoghegan, C. Yu, D.G. Winkler, and J.A. Latham Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts Bone 35 2004 448 454 (Pubitemid 38953192)
59. O. Leupin, I. Kramer, N.M. Collette, G.G. Loots, F. Natt, M. Kneissel, and H. Keller Control of the SOST bone enhancer by PTH using MEF2 transcription factors J Bone Miner Res 22 2007 1957 1967 (Pubitemid 351229312)
60. V. Krishnan, H.U. Bryant, and O.A. Macdougald Regulation of bone mass by Wnt signaling J Clin Invest 116 2006 1202 1209
61. J. Dong, J. Peng, H. Zhang, W.H. Mondesire, W. Jian, G.B. Mills, M.C. Hung, and F. Meric-Bernstam Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity Cancer Res 65 2005 1961 1972 (Pubitemid 40478626)